Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 12:17 PM
Ignite Modification Date:
2025-12-24 @ 12:17 PM
NCT ID:
NCT05675761
Brief Summary:
This study is a prospective, multicenter clinical study. It is intended to discuss the efficacy of starting Azovudine treatment as early as possible for all types of patients of COVID-19, the time of remission of specific symptoms, the proportion of patients with severe diseases, oxygen and conditions, and related adverse reactions, so as to understand the efficacy and safety of Azovudine treatment in all types of COVID-19, and provide real world data support for the treatment of the majority of COVID-19 patients.
Detailed Description:
1. To evaluate the clinical efficacy of Azovudine in the treatment of mild, moderate and severe COVID-19.
2. To explore the safety and adverse reactions of Azovudine in the whole population of COVID-19.
3. To explore the remission time of clinical symptoms, signs and images of patients with COVID-19 treated with Azovudine.
4. Explore the clinical guiding value of CORMB score.
Study:
NCT05675761
Study Brief:
Protocol Section:
NCT05675761